Peer-Reviewed Publication MEMORIAL SLOAN KETTERING CANCER CENTER AN IMMUNOFLUORESCENCE IMAGE OF AN AGED MOUSE LIVER. EXPRESSION OF Β-GALACTOSIDASE (WHITE) AND UPAR (YELLOW) IN SENESCENT CELLS SERVE AS TARGET FOR ENGINEERED CAR T CELLS. ELIMINATION OF THESE CELLS IMPROVED AGE-RELATED METABOLIC DYSFUNCTION. CREDIT: MEMORIAL SLOAN KETTERING CANCER CENTER HighlightsLaboratory research led by MSK and Cold Spring...
by H. Lee Moffitt Cancer Center & Research Institute BTN expression and spontaneous gamma/delta T cell infiltration in prostate tumors. (A) Bioinformatic analysis of TCR gamma variable regions (TRGV), BTN3A1, BTN2A1, ULBP1, MICA, MICB, and PSCA in bone and soft tissue biopsies from 118 individuals with mCRPC (SU2C/PCF dataset). (B) Specific comparison of TRGV expression in bone metastases....
by Friedrich–Alexander University Erlangen–Nurnberg Effects of CAR T cells on the manifestations of antisynthetase syndrome. (A) Neuropathology. Top, haematoxylin and eosin staining showing predominant perifascicular muscle atrophy and necrotic muscle fibers. Center left, staining for MHC-1 showing ubiquitous expression on muscle fibers with predominance at the perifascicular borders. Center right, connective tissue or perimysial fragmentation...
by University College London Credit: Unsplash/CC0 Public Domain A patient with relapsed T cell leukaemia has been given base-edited T-cells in a world-first use of a base-edited cell therapy, in a ‘bench-to-bedside’ collaboration between UCL and Great Ormond Street Hospital for Children (GOSH). The patient, 13-year-old Alyssa from Leicester, was diagnosed with T-cell acute lymphoblastic leukaemia (T-ALL)...
Roxanne Nelson, RN, BSN November 08, 2022 A novel approach in which two products were co-administered achieved a 99% complete response rate in children with relapsed or treatment-resistant B-cell acute lymphoblastic leukemia (B-ALL). In this trial, the largest study to date of a CAR T-cell therapy for such patients, the researchers co-administered two CAR T-cell therapies, one targeting...
by St. Jude Children’s Research Hospital Credit: CC0 Public Domain Scientists at St. Jude Children’s Research Hospital have developed the first GRP78 targeted chimeric antigen receptor (CAR) T cell. Their GRP78 CAR T cell successfully targeted and destroyed acute myelogenous leukemia (AML) cells in the lab. A paper on the work appeared today in Nature Communications....
By Angus Chen Jan. 14, 2022 MOLLY FERGUSON FOR STAT CAR-T cell therapy has been a boon for treating blood cancers. Since the technology was first brought to the clinic, CAR-T has offered patients months or years of life after they had exhausted all other treatment options and would have died within weeks. “It’s been...
by Perelman School of Medicine at the University of Pennsylvania Credit: CC0 Public Domain An experimental immunotherapy can temporarily reprogram patients’ immune cells to attack a specific target via only a single injection of messenger RNA (mRNA), similar to the mRNA-based COVID-19 vaccines, according to a new study from researchers in the Perelman School of...
by Memorial Sloan Kettering Cancer Center Electron microscopic image of a single human lymphocyte. Credit: Dr. Triche National Cancer Institute Immunotherapies called chimeric antigen receptor (CAR) T cells use genetically engineered versions of a patient’s own immune cells to fight cancer. These treatments have energized cancer care, especially for people with certain types of blood...
By Angus Chen Dec. 20, 2021 Reprints ADOBE As cancer-killing CAR-T cells course through the body, they make occasional pit stops at the gut. What they do there — and which gut microbes they meet up with — could potentially change the prospects of these engineered immune cells. Scientists are just beginning to tease apart the...
